Clinical Trial: Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)

U.S., Aug. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07147426) titled 'Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)' on Aug. 20.

Brief Summary: This study aims to explore the optimal course of neoadjuvant immunotherapy for HNSCC by comparing the efficacy and safety of 4 cycles and 2 cycles of neoadjuvant tislelizumab combined with chemotherapy.

Study Start Date: Sept. 20

Study Type: INTERVENTIONAL

Condition: Head &Amp; Neck Squamous Cell Carcinoma

Intervention: DRUG: Tislelizumab Combined With Chemotherapy for 4 cycles

Tislelizumab: 200mg, day 1, every 3 weeks for 4 cycl...